Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 23)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
9-Feb-10New Constructs, LLCN/AACOR: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10  View Abstract
9-Feb-10Pechala's ReportsLubomir PechalaACORDA THERAPEUTICS INC (ACOR=US) - REPORT FOR ACTIVE TRADERS4$25  View Abstract
9-Feb-10ValuEngine, Inc.N/AValuEngine Industry Report for BIOTECHNOLOGY18$49  View Abstract
9-Feb-10Stock Traders DailyThomas H. Kee Jr.Trading Report for (ACOR). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (ACOR).5$18  View Abstract
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for ACOR13$25  View Abstract
8-Feb-10PriceTarget Research, Inc.N/AAcorda Therapeutics has a current Overall Rating of D (Negative).7$25  View Abstract
7-Feb-10PriceTarget Research, Inc.N/ABiotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards.63$20  View Abstract
6-Feb-10Standard & Poor's Quantitative ReportN/AAcorda Therapeutics6$25  View Abstract
6-Feb-10Pechala's ReportsFrantisek PechalaACORDA THERAPTUTICS INC (ACOR=US) 12-months forecast1$15  View Abstract
6-Feb-10Pechala's ReportsLubomir PechalaACORDA THERAPTUTICS INC (ACOR=US) 2-weeks forecast1$10  View Abstract
Next 13
Brokerage Reports (Showing 1 to 1 of 1)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
22-Jan-10Thomson StreetEventsN/AACOR - Event Transcript of Acorda Therapeutics conference call, Jan. 22, 2010 / 5:30pm ET15$75  View Abstract
Independent Reports (Showing 1 to 10 of 22)
Release
Date [down]		 Contributor Author Title Pages Price More Info
9-Feb-10New Constructs, LLCN/AACOR: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10View Abstract
9-Feb-10Pechala's ReportsLubomir PechalaACORDA THERAPEUTICS INC (ACOR=US) - REPORT FOR ACTIVE TRADERS4$25View Abstract
9-Feb-10ValuEngine, Inc.N/AValuEngine Industry Report for BIOTECHNOLOGY18$49View Abstract
9-Feb-10Stock Traders DailyThomas H. Kee Jr.Trading Report for (ACOR). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (ACOR).5$18View Abstract
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for ACOR13$25View Abstract
8-Feb-10PriceTarget Research, Inc.N/AAcorda Therapeutics has a current Overall Rating of D (Negative).7$25View Abstract
7-Feb-10PriceTarget Research, Inc.N/ABiotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards.63$20View Abstract
6-Feb-10Standard & Poor's Quantitative ReportN/AAcorda Therapeutics6$25View Abstract
6-Feb-10Pechala's ReportsFrantisek PechalaACORDA THERAPTUTICS INC (ACOR=US) 12-months forecast1$15View Abstract
6-Feb-10Pechala's ReportsLubomir PechalaACORDA THERAPTUTICS INC (ACOR=US) 2-weeks forecast1$10View Abstract
Next 12

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.